NCT00716066View on ClinicalTrials.gov

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

December 30, 2025

Study Completion Date

January 31, 2030

Conditions
Autoimmune DiseaseNeurologic Autoimmune DiseaseAutologous Transplant AutoimmuneMultiple Sclerosis TransplantMS Stem Cell TransplantMultiple Sclerosis Stem Cell TransplantStiff Person SyndromeHCT for Neurologic Autoimmune DisordersCIDP TransplantMyasthenia Gravis TransplantAutoimmune Nervous System DisorderCentral Nervous System VasculitisCerebellar DegenerationChronic Inflammatory Demyelinating PolyneuropathyLambert Eaton Myasthenic SyndromeMyasthenia GravisNeuromyelitis OpticaOpsoclonus Myoclonus SyndromeRasmussen Subacute Encephalitis
Interventions
BIOLOGICAL

Anti-Thymocyte Globulin

Given IV

PROCEDURE

Autologous Hematopoietic Stem Cell Transplantation

Undergo autologous or syngeneic stem cell transplantation

DRUG

Carmustine

Given IV

DRUG

Cytarabine

Given IV

DRUG

Etoposide

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Melphalan

Given IV

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo autologous or syngeneic stem cell transplantation

DRUG

Prednisone

Given PO

PROCEDURE

Syngeneic Bone Marrow Transplantation

Undergo syngeneic bone marrow transplantation

Trial Locations (3)

80218

Colorado Blood Cancer Institute, Denver

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

98122-4307

Swedish Medical Center-First Hill, Seattle

All Listed Sponsors
lead

Fred Hutchinson Cancer Center

OTHER